European Regulators Approve Moderna’s mRNA Influenza–COVID Vaccine

It’s the first authorization for a combination shot against flu and COVID-19.

A health care worker in New York prepares a Moderna vaccine. Michael M. Santiago/Getty Images

European regulators on April 21 cleared a combination vaccine made by Moderna that targets COVID-19 and influenza.

Moderna’s messenger ribonucleic acid (mRNA) vaccine, mCombriax, is the first authorized combination flu–COVID shot after receiving clearance from the European Commission for individuals aged 50 and older.